Quick Answer
Exousia Bio, Inc. reported Cash and Equivalents of $7.9 thousand for fiscal year 2023.
Exousia Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $7.9K | -22.3% |
| 2022 | $10.1K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| August 31, 2023 | $1.3K | — | -83.2% |
| May 31, 2023 | $7.9K | -22.3% | +88.6% |
| February 28, 2023 | $4.2K | — | -58.8% |
| May 31, 2022 | $10.1K | — | — |
- Exousia Bio, Inc. showed a decrease of -22.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2023 period, Exousia Bio, Inc.’s cash and equivalents has declined by 22.3% (from $10.1 thousand to $7.9 thousand).
- The most recent figure is from Exousia Bio, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on September 1, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: